html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:40218993

Effects of Pomegranate Extract on Inflammatory Markers and Cardiometabolic Risk Factors in Adults Aged 55-70 Years: A Randomised Controlled Parallel Trial.

Nutrients2025The record ↗

Punica granatum

lowersInterleukin-6 concentration

What moved

1 findingHow to read these marks →

Decreases interleukin-6 concentration
moderate
“The PE resulted in a significant decrease in IL-6 levels compared to the placebo (by 5.47 ± 1.34 pg/mL (SE), p < 0.001).”
Study
RCT
Duration
3 months
Dose studied
two 370 mg capsules daily (740 mg/day) for 12 weeks
Population
Adults aged 55 to 70 years, normal weight or overweight, without diagnosed chronic disease, taking no blood-pressure, lipid or anti-inflammatory medication; control received maltodextrin placebo capsules

Study record

Design: randomised controlled trial
Species: human
Population: Apparently healthy adults aged 55-70 years, normal weight or overweight (BMI 18.5-29.9 kg/m2), no diagnosed chronic disease
Participants: 76
Comparator: placebo
Duration: 84 days
Endpoints measured: 19